Low risk of HBV reactivation in a large European cohort of HCV/HBV coinfected patients treated with DAA.
Jerzy JaroszewiczMałgorzata PawłowskaKrzysztof SimonDorota Zarębska-MichalukBeata LorencJakub KlapaczyńskiMagdalena Tudrujek-ZdunekMarek SitkoWłodzimierz MazurEwa JanczewskaKatarzyna PaluchDorota DybowskaIwona BuczyńskaAgnieszka Czauż-AndrzejukHanna BerakRafał KrygierMaciej PiaseckiBeata DobrackaJolanta CitkoAnna PiekarskaŁukasz SochaZbigniew DerońOlga TroninaŁukasz LauransJolanta BiałkowskaKrzysztof TomasiewiczWaldemar HalotaRobert FlisiakPublished in: Expert review of anti-infective therapy (2020)
Data from a large European cohort suggest a relatively low risk of HBV-reactivation during DAA-therapy for HCV infection in HBsAg(+) patients. In HBsAg(-)/anti-HBc(+) HBV-reactivation seems to be limited to subjects with immunodeficiency. Importantly, previous exposure to HBV and occult hepatitis B is present in a significant proportion of HCV-infected.